Shapiro Theresa A, Fahey Jed W, Dinkova-Kostova Albena T, Holtzclaw W David, Stephenson Katherine K, Wade Kristina L, Ye Lingxiang, Talalay Paul
Division of Clinical Pharmacology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Nutr Cancer. 2006;55(1):53-62. doi: 10.1207/s15327914nc5501_7.
Broccoli sprouts are widely consumed in many parts of the world. There have been no reported concerns with respect to their tolerance and safety in humans. A formal phase I study of safety, tolerance, and pharmacokinetics appeared justified because these sprouts are being used as vehicles for the delivery of the glucosinolate glucoraphanin and its cognate isothiocyanate sulforaphane [1-isothiocyanato-(4R)-(methylsulfinyl)butane] in clinical trials. Such trials have been designed to evaluate protective efficacy against development of neoplastic and other diseases. A placebo-controlled, double-blind, randomized clinical study of sprout extracts containing either glucosinolates (principally glucoraphanin, the precursor of sulforaphane) or isothiocyanates (principally sulforaphane) was conducted on healthy volunteers who were in-patients on our clinical research unit. The subjects were studied in three cohorts, each comprising three treated individuals and one placebo recipient. Following a 5-day acclimatization period on a crucifer-free diet, the broccoli sprout extracts were administered orally at 8-h intervals for 7 days (21 doses), and the subjects were monitored during this period and for 3 days after the last treatment. Doses were 25 micromol of glucosinolate (cohort A), 100 micromol of glucosinolate (cohort B), or 25 micromol of isothiocyanate (cohort C). The mean cumulative excretion of dithiocarbamates as a fraction of dose was very similar in cohorts A and B (17.8 +/- 8.6% and 19.6 +/- 11.7% of dose, respectively) and very much higher and more consistent in cohort C (70.6 +/- 2.0% of dose). Thirty-two types of hematology or chemistry tests were done before, during, and after the treatment period. Indicators of liver (transaminases) and thyroid [thyroid-stimulating hormone, total triiodothyronine (T3), and free thyroxine (T4)] function were examined in detail. No significant or consistent subjective or objective abnormal events (toxicities) associated with any of the sprout extract ingestions were observed.
西兰花芽苗菜在世界许多地区被广泛食用。目前尚未有关于其对人体耐受性和安全性的报道担忧。鉴于这些芽苗菜在临床试验中被用作萝卜硫苷葡萄糖萝卜硫素及其同源异硫氰酸酯萝卜硫素[1-异硫氰酸酯-(4R)-(甲基亚磺酰基)丁烷]的递送载体,因此开展一项关于安全性、耐受性和药代动力学的正式I期研究似乎是合理的。此类试验旨在评估对肿瘤及其他疾病发生的预防效果。对在我们临床研究单元住院的健康志愿者进行了一项安慰剂对照、双盲、随机临床研究,该研究使用了含有硫代葡萄糖苷(主要是萝卜硫苷,萝卜硫素的前体)或异硫氰酸酯(主要是萝卜硫素)的芽苗菜提取物。受试者被分为三个队列,每个队列包括三名接受治疗的个体和一名接受安慰剂的个体。在无十字花科蔬菜饮食的5天适应期后,每隔8小时口服西兰花芽苗菜提取物,持续7天(共21剂),在此期间及最后一次治疗后3天对受试者进行监测。剂量分别为25微摩尔硫代葡萄糖苷(A组)、100微摩尔硫代葡萄糖苷(B组)或25微摩尔异硫氰酸酯(C组)。A组和B组中二硫代氨基甲酸盐的平均累积排泄量占剂量的比例非常相似(分别为剂量的17.8±8.6%和19.6±11.7%),而C组则高得多且更一致(剂量的70.6±2.0%)。在治疗期之前、期间和之后进行了32种血液学或化学检测。详细检查了肝脏(转氨酶)和甲状腺[促甲状腺激素、总三碘甲状腺原氨酸(T3)和游离甲状腺素(T4)]功能指标。未观察到与任何芽苗菜提取物摄入相关的显著或一致的主观或客观异常事件(毒性)。